Esperion Therapeutics (ESPR) Expected to Post Earnings of -$1.56 Per Share

Equities research analysts expect that Esperion Therapeutics (NASDAQ:ESPR) will announce ($1.56) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Esperion Therapeutics’ earnings, with estimates ranging from ($1.96) to ($1.29). Esperion Therapeutics reported earnings per share of ($1.80) during the same quarter last year, which suggests a positive year over year growth rate of 13.3%. The company is scheduled to report its next earnings results on Thursday, May 3rd.

According to Zacks, analysts expect that Esperion Therapeutics will report full year earnings of ($5.61) per share for the current year, with EPS estimates ranging from ($6.58) to ($4.44). For the next year, analysts expect that the firm will post earnings of ($5.50) per share, with EPS estimates ranging from ($6.74) to ($4.54). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Esperion Therapeutics.

How to Become a New Pot Stock Millionaire

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.80) by $0.36. During the same period last year, the firm earned ($1.29) earnings per share.

A number of equities research analysts have recently weighed in on ESPR shares. BidaskClub raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 13th. UBS set a $88.00 target price on Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 17th. Credit Suisse Group assumed coverage on Esperion Therapeutics in a report on Wednesday, January 17th. They issued an “outperform” rating and a $103.00 target price for the company. Stifel Nicolaus set a $105.00 target price on Esperion Therapeutics and gave the company a “buy” rating in a report on Monday, January 15th. Finally, Citigroup lowered Esperion Therapeutics from a “buy” rating to a “neutral” rating and lifted their target price for the company from $77.00 to $96.00 in a report on Monday, January 22nd. Six equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $92.54.

Shares of NASDAQ ESPR traded down $0.62 during trading on Friday, reaching $75.78. The stock had a trading volume of 267,147 shares, compared to its average volume of 623,173. Esperion Therapeutics has a fifty-two week low of $30.95 and a fifty-two week high of $82.68. The stock has a market capitalization of $1,992.73, a PE ratio of -10.95 and a beta of 2.51.

In other Esperion Therapeutics news, Director Roger S. Newton sold 25,000 shares of Esperion Therapeutics stock in a transaction dated Thursday, March 29th. The stock was sold at an average price of $72.37, for a total transaction of $1,809,250.00. Following the completion of the sale, the director now directly owns 639,682 shares of the company’s stock, valued at approximately $46,293,786.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Nicole Vitullo sold 11,674 shares of Esperion Therapeutics stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $71.79, for a total value of $838,076.46. Following the sale, the director now directly owns 3,177 shares of the company’s stock, valued at $228,076.83. The disclosure for this sale can be found here. Company insiders own 32.50% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp increased its position in shares of Esperion Therapeutics by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 116,224 shares of the biopharmaceutical company’s stock worth $7,652,000 after purchasing an additional 852 shares in the last quarter. First Mercantile Trust Co. increased its position in Esperion Therapeutics by 56.0% in the 4th quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 1,519 shares during the period. Russell Investments Group Ltd. increased its position in Esperion Therapeutics by 8.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 25,072 shares of the biopharmaceutical company’s stock valued at $1,257,000 after acquiring an additional 1,913 shares during the period. American International Group Inc. increased its position in Esperion Therapeutics by 21.6% in the 3rd quarter. American International Group Inc. now owns 11,257 shares of the biopharmaceutical company’s stock valued at $564,000 after acquiring an additional 2,001 shares during the period. Finally, Moody Aldrich Partners LLC increased its position in Esperion Therapeutics by 26.1% in the 4th quarter. Moody Aldrich Partners LLC now owns 11,327 shares of the biopharmaceutical company’s stock valued at $746,000 after acquiring an additional 2,347 shares during the period. Institutional investors and hedge funds own 91.66% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Esperion Therapeutics (ESPR) Expected to Post Earnings of -$1.56 Per Share” was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thelincolnianonline.com/2018/04/18/esperion-therapeutics-espr-expected-to-post-earnings-of-1-56-per-share.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply